May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Bevacizumab Injection in Von Hippel Lindau Disease
O. Ustariz–Gonzalez; A. Suarez–Lincona; H. Quiroz–Mercado; J. Guerrero–Naranjo; A. Perez–Reguera; D. Moreno–Paramo; G. Alvarez–Rivera; A. Amaya–Espinosa; F. Furno–Sola
Author Affiliations & Notes
  • O. Ustariz–Gonzalez
    Retina, APEC, Mexico, Mexico
  • A. Suarez–Lincona
    Retina, APEC, Mexico, Mexico
  • H. Quiroz–Mercado
    Retina, APEC, Mexico, Mexico
  • J. Guerrero–Naranjo
    Retina, APEC, Mexico, Mexico
  • A. Perez–Reguera
    Retina, APEC, Mexico, Mexico
  • D. Moreno–Paramo
    Retina, APEC, Mexico, Mexico
  • G. Alvarez–Rivera
    Retina, APEC, Mexico, Mexico
  • A. Amaya–Espinosa
    Retina, APEC, Mexico, Mexico
  • F. Furno–Sola
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  O. Ustariz–Gonzalez, None; A. Suarez–Lincona, None; H. Quiroz–Mercado, None; J. Guerrero–Naranjo, None; A. Perez–Reguera, None; D. Moreno–Paramo, None; G. Alvarez–Rivera, None; A. Amaya–Espinosa, None; F. Furno–Sola, None.
  • Footnotes
    Support  Rioarronte Foundation
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4713. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Bevacizumab Injection in Von Hippel Lindau Disease
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      O. Ustariz–Gonzalez, A. Suarez–Lincona, H. Quiroz–Mercado, J. Guerrero–Naranjo, A. Perez–Reguera, D. Moreno–Paramo, G. Alvarez–Rivera, A. Amaya–Espinosa, F. Furno–Sola; Bevacizumab Injection in Von Hippel Lindau Disease . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4713.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To report safety and efficacy of intravitreal Bevacizumab (Avastin, Genetec. Inc) in two patients with Von Hippel Lindau Disease.

Methods: : Two eyes of 2 patients were treated with intravitreal Bevacizumab. Complete ophthalmic evaluation, visual acuity and fluorescein angiography (FA) were evaluated before and after 3 months of follow–up.

Results: : Both patients increase their visual acuity. One patient from –1.40 to –1.00 LogMAR and the other from –1.40 to –0.80 LogMAR. Vitreous opacity by ophthalmoscopy and color photos decreased in both eyes and FA showed less leakage.

Conclusions: : Intravitreal Bevacizumab was a safe treatment and decreased vascular permeability at 3 months follow–up.

Keywords: retina • tumors • retinal neovascularization 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept